Last checked at 
Braveheart Investment Group PLC - Dodworth, England-based investment company - Investee company Paraytec Ltd updates on its work in the development of potential use cases for its rapid test instrument, CX300. Explains it has been successfully tested in the detection of adeno-associated viruses, which are used in gene therapy. Notes this is important because virus-like particles such as adeno-associated viruses are used to encapsulate the new gene and deliver it into the body. Points out the target is to market the CX300 for use by all gene therapy manufacturers for in-process assessment of the quality of their adeno-associated virus products during research, development and, in due course, manufacturing.
Current stock price: 10.10 pence
12-month change: up 23%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.